Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment

Abstract

Sulfonylureas are insulin secretagogues which act in pancreatic β cells by blocking the K_ATP channels encoded by KCNJ11 and ABCC8 genes. In the present study, a pharmacoepigenetic approach was applied for the first time, investigating the correlation of KCNJ11 and ABCC8 gene promoter methylation with sulfonylureas-induced mild hypoglycemic events as well as the KCNJ11 E23K genotype. Sodium bisulfite-treated genomic DNA of 171 sulfonylureas treated T2DM patients previously genotyped for KCNJ11 E23K, including 88 that had experienced drug-associated hypoglycemia and 83 that had never experienced hypoglycemia, were analyzed for DNA methylation of KCNJ11 and ABCC8 gene promoters via quantitative Methylation-Specific PCR. KCNJ11 methylation was detected in 19/88 (21.6%) of hypoglycemic and in 23/83 (27.7%) of non-hypoglycemic patients (p=0.353), while ABCC8 methylation in 6/83 (7.2%) of non-hypoglycemic and none (0/88) of the hypoglycemic patients (p=0.012). Methylation in at least one promoter (KCNJ11 or ABCC8) was significantly associated with non-hypoglycemic patients who are carriers of KCNJ11 EK allele (p=0.030). Our data suggest that ABCC8 but not KCNJ11 methylation is associated to hypoglycemic events in sulfonylureas-treated T2DM patients. Furthermore, it is demonstrated that the KCNJ11 E23K polymorphism in association to either of the two genes’ DNA methylation may have protective role against sulfonylurea-induced hypoglycemia.

Key words

epigenetics - methylation - promoter - receptor - adverse effect

• References

• 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine 2006; 3: e442
• 2 Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: The influence of drug target and diabetes risk polymorphisms. Expert review of cardiovascular therapy 2010; 8: 359-372
• 3 Frier BM. Hypoglycaemia in diabetes mellitus: Epidemiology and clinical implications. Nature reviews Endocrinology 2014; 10: 711-722
• 4 Barendse S, Singh H, Frier BM. et al. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabetic medicine : A journal of the British Diabetic Association 2012; 29: 293-302
• 5 Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: Current data and pharmacoepigenomic perspective. Pharmacogenomics 2011; 12: 1161-1191
• 6 Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: The role of drug transporter polymorphisms. Expert opinion on drug metabolism & toxicology 2008; 4: 529-544
• 7 Kirchheiner J, Roots I, Goldammer M. et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clinical pharmacokinetics 2005; 44: 1209-1225
• 8 Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Experimental and clinical endocrinology & diabetes : Official journal, German Society of Endocrinology [and] German Diabetes Association 2003; 111: 405-414
• 9 Proks P, Reimann F, Green N. et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl. 03) S368-S376
• 10 Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-1358
• 11 Klen J, Dolzan V, Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology 2014; 70: 421-428
• 12 Javorsky M, Klimcakova L, Schroner Z. et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European journal of internal medicine 2012; 23: 245-249
• 13 Florez JC, Burtt N, de Bakker PI. et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004; 53: 1360-1368
• 14 Ragia G, Tavridou A, Petridis I. et al. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes research and clinical practice 2012; 98: 119-124
• 15 Sato R, Watanabe H, Genma R. et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 2010; 11: 1743-1750
• 16 Holstein A, Hahn M, Stumvoll M. et al. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2009; 41: 387-390
• 17 Egger G, Liang G, Aparicio A. et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463
• 18 Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends in Pharmacological Sciences 2014; 35: 384-396
• 19 Ingelman-Sundberg M, Sim SC, Gomez A. et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & therapeutics 2007; 116: 496-526
• 20 Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clinical pharmacology and therapeutics 2012; 92: 727-736
• 21 de Mello VD, Pulkkinen L, Lalli M. et al. DNA methylation in obesity and type 2 diabetes. Annals of medicine 2014; 46: 103-113
• 22 Seaquist ER, Anderson J, Childs B. et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes care 2013; 36: 1384-1395
• 23 ADA. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes care 2005; 28: 1245-1249
• 24 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabetic medicine : A journal of the British Diabetic Association 2001; 18: 690-705
• 25 Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics (Oxford, England) 2002; 18: 1427-1431
• 26 Lu L, Katsaros D, de la Longrais IA. et al. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer research 2007; 67: 10117-10122
• 27 Panagopoulou M, Lambropoulou M, Balgkouranidou I et al. Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk HPV infection and cancer. Tumor Biology 2017; 39:
• 28 Hall E, Volkov P, Dayeh T. et al. Sex differences in the genome-wide DNA methylation pattern and impact on gene expression, microRNA levels and insulin secretion in human pancreatic islets. Genome biology 2014; 15: 522
• 29 Ling C, Del Guerra S, Lupi R. et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008; 51: 615-622
• 30 Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009; 58: 2718-2725
• 31 Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman medical journal 2012; 27: 269-273
• 32 Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management 2013; 9: 155-163
• 33 Ragia G, Tavridou A, Elens L. et al. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Experimental and clinical endocrinology & diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association 2014; 122: 60-63
• 34 van Leeuwen N, Swen JJ, Guchelaar HJ. et al. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clinical pharmacokinetics 2013; 52: 833-854
• 35 Hicks JK, Swen JJ, Thorn CF. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical pharmacology and therapeutics 2013; 93: 402-408
• 36 Zhong XB, Leeder JS. Epigenetic regulation of ADME-related genes: Focus on drug metabolism and transport. Drug metabolism and disposition: the biological fate of chemicals 2013; 41: 1721-1724
• 37 Johnson JS, Evans-Molina C. Translational implications of the beta-cell epigenome in diabetes mellitus. Translational research : The Journal of Laboratory and Clinical Medicine 2015; 165: 91-101
• 38 Candelaria M, de la Cruz-Hernandez E, Perez-Cardenas E. et al. Pharmacogenetics and pharmacoepigenetics of gemcitabine. Medical oncology (Northwood, London, England) 2010; 27: 1133-1143
• 39 Thon N, Kreth S, Kreth FW. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets and therapy 2013; 6: 1363-1372
• 40 Nasr R, Sleiman F, Awada Z. et al. The pharmacoepigenetics of drug metabolism and transport in breast cancer: Review of the literature and in silico analysis. Pharmacogenomics 2016; 17: 1573-1585
• 41 Powell TR, Smith RG, Hackinger S. et al. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Translational psychiatry 2013; 3: e300
• 42 Domschke K, Tidow N, Schwarte K. et al. Pharmacoepigenetics of depression: No major influence of MAO-A DNA methylation on treatment response. Journal of Neural Transmission (Vienna, Austria: 1996) 2015; 122: 99-108
• 43 Ronn T, Ling C. DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. Epigenomics 2015; 7: 451-460
• 44 Bell CG, Finer S, Lindgren CM. et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the fto type 2 diabetes and obesity susceptibility locus. PloS one 2010; 5: e14040